IκBKβ and NFκB1, NSAID use and risk of colorectal cancer in the colon cancer family registry

Carcinogenesis

Volumn 34, Issue 1, 2013, Pages 79-85

  Seufert, Brenna L ^a   Poole, Elizabeth M ^b   Whitton, John ^a   Xiao, Liren ^a   Makar, Karen W ^a   Campbell, Peter T ^c   Kulmacz, Richard J ^d   Baron, John A ^e   Newcomb, Polly A ^a   Slattery, Martha L ^f   Potter, John D ^a,g   Ulrich, Cornelia M ^a,h  

^a USA   (United States)

^b BRIGHAM AND WOMEN S HOSPITAL   (United States)

^c AMERICAN CANCER SOCIETY   (United States)

^d UNIVERSITY OF TEXAS   (United States)

^e UNIVERSITY OF NORTH CAROLINA   (United States)

^f UNIVERSITY OF UTAH HEALTH SCIENCES CENTER   (United States)

^g MASSEY UNIVERSITY   (New Zealand)

^h GERMAN CANCER RESEARCH CENTER DKFZ   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

I KAPPA B KINASE BETA; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN 1; NONSTEROID ANTIINFLAMMATORY AGENT; UNCLASSIFIED DRUG;

ADULT; ARTICLE; CANCER RISK; COLON CANCER; COLORECTAL CANCER; CONTROLLED STUDY; DRUG USE; FEMALE; GENETIC ASSOCIATION; GENETIC RISK; GENETIC VARIABILITY; HUMAN; INTRON; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; SIBLING; SINGLE NUCLEOTIDE POLYMORPHISM;

ADULT; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; COLORECTAL NEOPLASMS; FEMALE; GENETIC PREDISPOSITION TO DISEASE; HUMANS; MALE; MIDDLE AGED; NF-KAPPA B; POLYMORPHISM, SINGLE NUCLEOTIDE; REGISTRIES;

EID: 84872151457     PISSN: 01433334     EISSN: 14602180     Source Type: Journal    
DOI: 10.1093/carcin/bgs296     Document Type: Article

References (51)

1. Fantini, M.C. et al. (2008) Cytokines: from gut inflammation to colorectal cancer. Curr. Drug Targets, 9, 375-380.
2. Rizzo, A. et al. (2011) Intestinal inflammation and colorectal cancer: a double-edged sword? World J. Gastroenterol., 17, 3092-3100.
3. Ulrich, C.M. et al. (2006) Non-steroidal anti-inflammatory drugs for cancer prevention: promise, perils and pharmacogenetics. Nat. Rev. Cancer, 6, 130-140.
4. Rhodes, J.M. et al. (2002) Inflammation and colorectal cancer: IBDassociated and sporadic cancer compared. Trends Mol. Med., 8, 10-16.
5. Wang, S. et al. (2009) NF-kappaB signaling pathway, inflammation and colorectal cancer. Cell. Mol. Immunol., 6, 327-334.
6. Sakamoto, K. et al. (2009) Constitutive NF-kappaB activation in colorectal carcinoma plays a key role in angiogenesis, promoting tumor growth. Clin. Cancer Res., 15, 2248-2258.
7. Baud, V. et al. (2009) Is NF-kappaB a good target for cancer therapy? Hopes and pitfalls. Nat. Rev. Drug Discov., 8, 33-40.
8. Pomerantz, J.L. et al. (2002) Two pathways to NF-kappaB. Mol. Cell, 10, 693-695.
9. Curtin, K. et al. (2010) Exploring multilocus associations of inflammation genes and colorectal cancer risk using hapConstructor. BMC Med. Genet., 11, 170.
10. Andersen, V. et al. (2010) Polymorphisms in NFkB, PXR, LXR and risk of colorectal cancer in a prospective study of Danes. BMC Cancer, 10, 484.
11. Coghill, A.E. et al. (2011) Genetic variation in inflammatory pathways is related to colorectal cancer survival. Clin. Cancer Res., 17, 7139-7147.
12. Algra, A.M. et al. (2012) Effects of regular aspirin on long-term cancer incidence and metastasis: a systematic comparison of evidence from observational studies versus randomised trials. Lancet Oncol., 13, 518-527.
13. Flossmann, E. et al. (2007) Effect of aspirin on long-term risk of colorectal cancer: consistent evidence from randomised and observational studies. Lancet, 369, 1603-1613.
14. Dube, C. et al. (2007) The use of aspirin for primary prevention of colorectal cancer: a systematic review prepared for the U.S. Preventive Services Task Force. Ann. Intern. Med., 146, 365-375.
15. Cross, J.T. et al. (2008) A review of gene-drug interactions for nonsteroidal anti-inflammatory drug use in preventing colorectal neoplasia. Pharmacogenomics J., 8, 237-247.
16. Karin, M. et al. (2004) The IKK NF-kappa B system: a treasure trove for drug development. Nat. Rev. Drug Discov., 3, 17-26.
17. Yin, M.J. et al. (1998) The anti-inflammatory agents aspirin and salicylate inhibit the activity of I(kappa)B kinase-beta. Nature, 396, 77-80.
18. Din, F.V. et al. (2004) Evidence for colorectal cancer cell specificity of aspirin effects on NF kappa B signalling and apoptosis. Br. J. Cancer, 91, 381-388.
19. Yamamoto, Y. et al. (1999) Sulindac inhibits activation of the NF-kappaB pathway. J. Biol. Chem., 274, 27307-27314.
20. Stark, L.A. et al. (2001) Aspirin-induced activation of the NF-kappaB signaling pathway: a novel mechanism for aspirin-mediated apoptosis in colon cancer cells. FASEB J., 15, 1273-1275.
21. Poole, E.M. et al. (2007) Genetic variability in prostaglandin synthesis, fish intake and risk of colorectal polyps. Carcinogenesis, 28, 1259-1263.
22. Poole, E.M. et al. (2012) Genetic variability in IL23R and risk of colorectal adenoma and colorectal cancer. Cancer Epidemiol., 36, e104-e110.
23. Poole, E.M. et al. (2010) Genetic variation in prostaglandin E2 synthesis and signaling, prostaglandin dehydrogenase, and the risk of colorectal adenoma. Cancer Epidemiol. Biomarkers Prev., 19, 547-557.
24. Ulrich, C.M. et al. (2004) Polymorphisms in PTGS1 (=COX-1) and risk of colorectal polyps. Cancer Epidemiol. Biomarkers Prev., 13, 889-893.
25. Ulrich, C.M. et al. (2005) PTGS2 (COX-2) -765G > C promoter variant reduces risk of colorectal adenoma among nonusers of nonsteroidal antiinflammatory drugs. Cancer Epidemiol. Biomarkers Prev., 14, 616-619.
26. Poole, E.M. et al. (2006) Prostacyclin synthase and arachidonate 5-lipoxygenase polymorphisms and risk of colorectal polyps. Cancer Epidemiol. Biomarkers Prev., 15, 502-508.
27. Newcomb, P.A. et al. (2007) Colon Cancer Family Registry: an international resource for studies of the genetic epidemiology of colon cancer. Cancer Epidemiol. Biomarkers Prev., 16, 2331-2343.
28. Levine, A.J. et al. (2010) A candidate gene study of folate-associated one carbon metabolism genes and colorectal cancer risk. Cancer Epidemiol. Biomarkers Prev., 19, 1812-1821.
29. Thorisson, G.A. et al. (2005) The International HapMap Project Web site. Genome Res., 15, 1592-1593.
30. Sherry, S.T. et al. (2001) dbSNP: the NCBI database of genetic variation. Nucleic Acids Res., 29, 308-311.
31. Shen, R. et al. (2005) High-throughput SNP genotyping on universal bead arrays. Mutat. Res., 573, 70-82.
32. Levine, A.J. et al. (2010) Genetic variability in the MTHFR gene and colorectal cancer risk using the colorectal cancer family registry. Cancer Epidemiol. Biomarkers Prev., 19, 89-100.
33. Conneely, K.N. et al. (2007) So many correlated tests, so little time! Rapid adjustment of P values for multiple correlated tests. Am. J. Hum. Genet., 81, 1158-1168.
34. Benjamini, Y. et al. (2001) Controlling the false discovery rate in behavior genetics research. Behav. Brain Res., 125, 279-284.
35. Benjamini, Y. et al. (1995) Controlling the false discovery rate-a practical and powerful approach to multiple testing. J. R. Stat. Soc. Ser. B-Methodological, 57, 289-300.
36. Kucharczak, J. et al. (2003) To be, or not to be: NF-kappaB is the answer-role of Rel/NF-kappaB in the regulation of apoptosis. Oncogene, 22, 8961-8982.
37. Luo, J.L. et al. (2005) IKK/NF-kappaB signaling: balancing life and death-a new approach to cancer therapy. J. Clin. Invest., 115, 2625-2632.
38. Barnes, P.J. et al. (1997) Nuclear factor-kappaB: a pivotal transcription factor in chronic inflammatory diseases. N. Engl. J. Med., 336, 1066-1071.
39. LeRoy, E.C. et al. (2011) Genes in the insulin and insulin-like growth factor pathway and odds of metachronous colorectal neoplasia. Hum. Genet., 129, 503-512.
40. Kumar, P. et al. (2009) Predicting the effects of coding non-synonymous variants on protein function using the SIFT algorithm. Nat. Protoc., 4, 1073-1081.
41. Witte, J.S. et al. (1999) Asymptotic bias and efficiency in case-control studies of candidate genes and gene-environment interactions: basic family designs. Am. J. Epidemiol., 149, 693-705.
42. Kent, W.J. et al. (2002) The human genome browser at UCSC. Genome Res., 12, 996-1006.
43. Slattery, M.L. et al. (2007) CDX2 VDR polymorphism and colorectal cancer. Cancer Epidemiol. Biomarkers Prev., 16, 2752-2755.
44. Slattery, M.L. et al. (2005) Energy balance, insulin-related genes and risk of colon and rectal cancer. Int. J. Cancer, 115, 148-154.
45. Slattery, M.L. et al. (2004) Dietary calcium, vitamin D, VDR genotypes and colorectal cancer. Int. J. Cancer, 111, 750-756.
46. Kapiteijn, E. et al. (2001) Mechanisms of oncogenesis in colon versus rectal cancer. J. Pathol., 195, 171-178.
47. Frattini, M. et al. (2004) Different genetic features associated with colon and rectal carcinogenesis. Clin. Cancer Res., 10(12 Pt 1), 4015-4021.
48. Süleyman, H. et al. (2007) Anti-inflammatory and side effects of cyclooxygenase inhibitors. Pharmacol. Rep., 59, 247-258.
49. Ruder, E.H. et al. (2011) Non-steroidal anti-inflammatory drugs and colorectal cancer risk in a large, prospective cohort. Am. J. Gastroenterol., 106, 1340-1350.
50. Langman, M.J. et al. (1999) Adverse upper gastrointestinal effects of rofecoxib compared with NSAIDs. JAMA, 282, 1929-1933.
51. Gauderman, W.J. (2002) Sample size requirements for matched case-control studies of gene-environment interaction. Stat. Med., 21, 35-50.